Statement of financial position of PolyPeptide Group AG

As at 31 December

Assets, kCHF

Note

2025

2024

 

 

 

 

Current assets

 

 

 

Cash and cash equivalents

1

400

224

Loan to group companies

 

90,972

65,459

Other receivables from third parties

 

330

Other receivables from group companies

 

41,396

40,479

Accrued income and prepaid expenses

 

724

691

Total current assets

 

133,822

106,853

 

 

 

 

Non-current assets

 

 

 

Loan to group companies

 

125,254

126,575

Financial assets

3

7,525

5,221

Investments

2

155,738

851,700

Tangible assets

 

490

586

Total non-current assets

 

289,007

984,082

 

 

 

 

Total assets

 

422,829

1,090,935

Statement of financial position of PolyPeptide Group AG (continued)

As at 31 December

Liabilities, kCHF

Note

2025

2024

 

 

 

 

Current liabilities

 

 

 

Other liabilities due to third parties

 

967

1,354

Interest-bearing liabilities due to shareholder

 

293

28,730

Accrued expenses and deferred income

 

2,465

36

Total short-term liabilities

 

3,725

30,120

 

 

 

 

Non-current liabilities

 

 

 

Interest-bearing liabilities due to third parties

 

83,822

37,647

Interest-bearing liabilities due to shareholder

 

18,627

Total long-term liabilities

 

102,449

37,647

 

 

 

 

Shareholders' equity

 

 

 

Share capital

4

331

331

Statutory capital reserves

 

 

 

Reserves from capital contribution

5

2,104,803

2,104,803

Other capital reserves

 

4,949

4,949

Treasury shares

6

-7,232

-9,043

Net loss brought forward

 

-1,077,872

-1,412,542

Net loss on sale of treasury shares

 

-1,534

-1,102

Net loss/profit for the year

 

-706,790

335,772

Total shareholders' equity

 

316,655

1,023,168

 

 

 

 

Total liabilities and shareholders' equity

 

422,829

1,090,935